Skip to Content

Enzolytics Inc ENZC

Morningstar Rating
$0.01 0.00 (5.20%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ENZC is trading at a 49% discount.
Price
$0.01
Fair Value
$7.16
Uncertainty
Extreme
1-Star Price
$7.59
5-Star Price
$4.76
Economic Moat
Cpgh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENZC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.13
Bid/Ask
$0.01 / $0.01
Market Cap
$25.91 Mil
Volume/Avg
6.2 Mil / 7.5 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
1

Comparables

Valuation

Metric
ENZC
MRSN
CLDX
Price/Earnings (Normalized)
Price/Book Value
14.695.45
Price/Sales
14.15294.86
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ENZC
MRSN
CLDX
Quick Ratio
0.013.2913.69
Current Ratio
0.063.3613.87
Interest Coverage
−92.76−44.11
Quick Ratio
ENZC
MRSN
CLDX

Profitability

Metric
ENZC
MRSN
CLDX
Return on Assets (Normalized)
−611.82%−49.57%−30.49%
Return on Equity (Normalized)
−211.52%−33.19%
Return on Invested Capital (Normalized)
−146.81%−32.85%
Return on Assets
ENZC
MRSN
CLDX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCxvksbzrhWrtz$570.1 Bil
VRTX
Vertex Pharmaceuticals IncGwjvmdtpKzgvjs$107.8 Bil
REGN
Regeneron Pharmaceuticals IncHztrdsgLmkcgv$105.6 Bil
MRNA
Moderna IncVqgplflSbjh$42.3 Bil
ARGX
argenx SE ADRVfdbfrtcWpb$23.7 Bil
BNTX
BioNTech SE ADRGhmcgkdvMfm$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncNssggvjKxvpn$19.4 Bil
BMRN
Biomarin Pharmaceutical IncZflypsgyJtfndp$16.7 Bil
RPRX
Royalty Pharma PLC Class ALqjhyyxhjdPsfxyfz$13.6 Bil
INCY
Incyte CorpDxssbdsGmlrd$12.8 Bil

Sponsor Center